Sectors
AVBP
ArriVent BioPharma, Inc.
28.90
2 x 22.54
2 x 38.95
bid
ask
+
0.54
1.90%
2 @ 07:30 PM
28.90 +0.00 (0.00%)
| Ytd | 43.64% | |
| 1y | 55.54% |
28.62
day range
29.64
17.00
52 week range
35.83
| Open | 29.00 | Prev Close | 28.36 | Low | 28.62 | High | 29.64 | Mkt Cap | 1.42B |
| Vol | 1.24M | Avg Vol | 534.81K | EPS | -3.55 | P/E | N/A | Forward P/E | -7.59 |
| Beta | 1.36 | Short Ratio | 21.25 | Inst. Own | 98.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 30.35 | 200-d Avg | 27.05 | 1yr Est | 44.70 |
| Income Statement | |||
| Operating Expenses | 52.69M | ||
| Research and Development Expense | 42.34M | ||
| Selling, General and Administrative Expense | 10.35M | ||
| Operating Income | -52.69M | ||
| Net Income | -49.89M | ||
| Net Income Common Stock | -49.89M | ||
| Net Income Common Stock (USD) | -49.89M | ||
| Consolidated Income | -49.89M | ||
| Earnings per Basic Share | -1.05 | ||
| Earnings per Basic Share (USD) | -1.05 | ||
| Earnings per Diluted Share | -1.05 | ||
| Earning Before Interest & Taxes (EBIT) | -49.89M | ||
| Earning Before Interest & Taxes (USD) | -49.89M | ||
| Weighted Average Shares | 47.61M | ||
| Weighted Average Shares Diluted | 47.61M | ||
| Balance Sheet | |||
| Cash and Equivalents | 154.68M | ||
| Cash and Equivalents (USD) | 154.68M | ||
| Investments | 218.44M | ||
| Investments Current | 218.44M | ||
| Current Assets | 394.17M | ||
| Property, Plant & Equipment Net | 370.00K | ||
| Total Assets | 394.72M | ||
| Debt Current | 318.00K | ||
| Total Debt | 351.00K | ||
| Current Liabilities | 27.84M | ||
| Debt Non-Current | 33.00K | ||
| Total Liabilities | 27.88M | ||
| Accumulated Retained Earnings (Deficit) | -497.85M | ||
| Accumulated Other Comprehensive Income | -267.00K | ||
| Shareholders Equity | 366.84M | ||
| Shareholders Equity (USD) | 366.84M | ||
| Assets Non-Current | 545.00K | ||
| Total Debt (USD) | 351.00K | ||
| Liabilities Non-Current | 33.00K | ||
| Trade and Non-Trade Payables | 2.22M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | 86.09M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 92.58M | ||
| Issuance (Purchase) of Equity Shares | 86.09M | ||
| Net Cash Flow from Investing | 46.07M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 46.07M | ||
| Net Cash Flow from Operations | -39.58M | ||
| Share Based Compensation | 6.67M | ||